Press Releases
Our team at Pharmafocuseurope.com believes that press releases are an important marketing tool for highlighting a client's corporate message and ensuring it reaches their target audience. The feature can be used to publish business agreements, annual reports, financial results, corporate performances, important announcements, and any other important information that needs to be communicated to the target audience. Pharma companies can also use it to launch new products and promote existing ones.
F-star, an invoX Company, Announces Strategic Collaboration and Licence Agreement with Takeda to Discover and Develop Next-Generation Multi-Specific Antibodies
Thursday, July 06, 2023Fstar Therapeutics an invoX company Fstar today announced that it has entered into a strategic discovery collaboration and licence agreement with Takeda The collaboration will leverage Fstars proprietary fullyhuman Fcab and tetravalent mAb platforms...
Cipher Partner, Moberg Pharma Announces Approval for MOB-015 in the European Union
Thursday, July 06, 2023Cipher Pharmaceuticals Inc TSX CPH Cipher or the Company today announced that the Companys partner Moberg Pharma AB Moberg Pharma has obtained European Union approval for MOB nail fungus treatment as a result of demonstrating superior levels of mycol...
Janssen Announces Positive Topline Results for JNJ-2113--a Novel, First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
Wednesday, July 05, 2023The Janssen Pharmaceutical Companies of Johnson Johnson today announced positive topline results from its Phase b FRONTIER clinical trial evaluating the novel first and only oral interleukin receptor ILR antagonist peptide JNJ in adult patients wit...
Protagonist Therapeutics Announces Positive Topline Results with JNJ-2113, the First and Only Oral IL-23 Receptor Antagonist Peptide in Development for Moderate-to-Severe Plaque Psoriasis
Wednesday, July 05, 2023Protagonist Therapeutics Inc Protagonist or the Company today announced positive topline results from the Phase b FRONTIER clinical trial evaluating the oral interleukin receptor ILR antagonist JNJ formerly PN in adult patients with moderatetosevere...
Coherus Launches YUSIMRY™, a Biosimilar of Humira®, at $995 per Carton in U.S.
Tuesday, July 04, 2023Coherus BioSciences Inc Coherus Nasdaq CHRS today announced that YUSIMRY adalimumabaqvh is now available for commercial sale in the United States at a list price of per carton for two mg mL autoinjectors representing a discount of more than to Hum...
NorthX Biologics, a leading Nordic development and manufacturing organisation announces acquisition of a biologics manufacturing unit from Valneva
Tuesday, July 04, 2023NorthX Biologics NorthX a leading Nordic development and manufacturing organisation with a focus on advanced biologics CGT cell and gene therapy and vaccines announced today the successful acquisition of the Stockholmbased Clinical Trial Manufacturin...
Novartis signs agreement to divest ‘front of eye’ ophthalmology assets in line with focused strategy
Saturday, July 01, 2023Novartis announced today that it has signed an agreement to divest front of eye ophthalmology assets to Bausch Lomb a global eye health company in a transaction valued up to USD billion including USD billion in upfront cash plus additional milesto...
Univercells Technologies Acquired by Donaldson Company
Saturday, July 01, 2023Gamma Biosciences a life sciences platform created by global investment firm KKR to address the advanced therapy bioprocessing market today announced that its operating company Univercells Technologies UT a leading provider of novel biomanufacturing...
Tevogen Bio to Become Publicly Listed on NYSE via Business Combination with Semper Paratus Acquisition Corporation
Friday, June 30, 2023Tevogen Bio Inc a clinicalstage specialty immunotherapy biotech pioneer developing offtheshelf genetically unmodified T cell therapeutics in virology oncology and neurology and Semper Paratus Acquisition Corporation a publicly traded special purpose...
Sangamo Therapeutics and Voyager Therapeutics Enter License Agreement for Epigenetic Regulation Treatment of Prion Disease
Friday, June 30, 2023Sangamo Therapeutics Inc Nasdaq SGMO a genomic medicine company and Voyager Therapeutics Inc Nasdaq VYGR today announced the parties have entered into a definitive license agreement for a potential treatment of prion disease Using its proprietary epi...
